Turning Point Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TPTX research report →
Range $73.6 – $73.6
Price Chart
About the company
Turning Point Therapeutics is a biopharmaceutical firm specializing in precision oncology, currently in the clinical development stage. The company is dedicated to discovering and advancing targeted therapies that address the underlying genetic causes of cancer. They have developed a portfolio of innovative tyrosine kinase inhibitors (TKIs) designed to treat cancer patients, including those who have not yet received TKI treatment and those who have previously been treated with TKIs.
- CEO
- Athena Maria Countouriotis
- IPO
- 2019
- Employees
- 267
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on TPTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- -13.04
- PEG
- 0.22
- P/S
- 0.00
- P/B
- 3.23
- EV/EBITDA
- 1.82
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -767.30%
- Net Margin
- -767.30%
- ROE
- -22.92%
- ROIC
- -24.64%
Latest fiscal year · YoY change
- Revenue
- $30.83M+23.3%
- Gross Profit
- $30.83M+123315900.0%
- Op Income
- $-236,551,000
- Net Income
- $-236,551,000-50.4%
- EPS
- $-5.79-50.4%
- OCF Growth
- -85.9%
- FCF Growth
- -86.0%
- Beta
- -0.19
- RSI (14)
- 75
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Turning Point ended Q3 2021 with about $1 billion in cash, continued pipeline/regulatory progress for repotrectinib and elzovantinib, and said it remains on track toward key 2022 data and FDA interactions.· November 9, 2021
- Repotrectinib received a second breakthrough therapy designation, and management is planning a Type B FDA meeting next month for enteric/solid tumor registration next steps.
- The company reiterated that top-line blinded independent central review data from all ROS1+ TRIDENT-1 cohorts is expected in Q2 2022, with a pre-NDA FDA meeting also anticipated then.
- Elzovantinib got FDA feedback to study an additional intermediate dose level; the company is enrolling that cohort and still expects to move toward a Phase II portion in 2022.
- Turning Point ended the quarter with about $1 billion in cash and said current resources should fund operations into 2024.
- Management continues to build commercial and medical affairs infrastructure ahead of a potential repotrectinib launch, while discovery work aims to nominate two new candidates in 2H 2022.
Operating expenses were $67.1 million in Q3 2021 versus $43.5 million in Q3 2020. Research and development expense was $48.9 million, up from $32.2 million a year ago, and general and administrative expense was $18.2 million versus $11.3 million. Net cash used in the first nine months of 2021 was $86.5 million, and cash, cash equivalents, and marketable securities totaled approximately $1 billion at September 30. The company did not report revenue or EPS on this call. Forward-looking guidance: repotrectinib top-line BICR data from all ROS1+ cohorts is planned for Q2 2022, with a pre-NDA FDA meeting also in Q2 2022; a Type B FDA meeting for enteric-positive TKI-pretreated disease is planned next month. For elzovantinib, FDA feedback on MET-amplified gastric cancer is expected next month, and SHIELD-2 is targeted for mid-2022 pending IND clearance in the first half of 2022. Cash is expected to fund current operations into 2024.
Athena Countouriotis emphasized that the company has scaled from one Phase I asset to four clinical-stage assets across six ongoing trials, supported by nine regulatory designations and a growing team. Her tone was confident and focused on differentiation, especially for repotrectinib, which she described as having best-in-class potential in ROS1+ and promising activity in NTRK. She also framed 2022 as a regulatory-heavy year, with multiple FDA interactions, launch-readiness work, and discovery milestones ahead.
Paolo Tombesi focused on spending trends and the balance sheet. He said Q3 operating expenses were $67.1 million, driven mainly by R&D investment in repotrectinib, elzovantinib, TPX-0046, TPX-0131, discovery, and personnel, while G&A rose to $18.2 million due to personnel and launch-readiness costs. He highlighted $86.5 million of net cash used in the first nine months of 2021 and approximately $1 billion of cash and marketable securities at quarter-end, saying that should fund operations into 2024.
Analysts pressed on how quickly elzovantinib could enroll the additional 6 to 10 patients at the intermediate dose and whether more data from the Phase I expansion would be shown publicly in early 2022. Management said screening has started, they are enrolling as quickly as possible, and they expect a robust dataset for the FDA, but they would not promise a public readout before the agency meeting. On repotrectinib, analysts asked what the Q2 2022 FDA meeting will decide; management said the key question is whether the FDA will accept six months of follow-up for a pre-NDA filing versus reverting to 12 months. Questions also focused on comparing repotrectinib with Rozlytrek’s label and launch; Athena argued the competitor’s performance has been weaker than its label implied and said Turning Point is pursuing a faster path if the FDA agrees.
The bull case from this call is that Turning Point has multiple shots on goal, but repotrectinib remains the centerpiece with two breakthrough designations and a potentially faster regulatory path. Management sounded confident that the company’s datasets, FDA dialogue, and commercial preparation could support a meaningful launch opportunity.
The main risks are regulatory and execution-related: FDA feedback could still require more follow-up, especially on repotrectinib, and elzovantinib still needs more data at the intermediate dose before Phase II can proceed. Spending is also rising quickly, with operating expenses well above last year, so success depends on converting the pipeline and regulatory momentum into approvable data.
AI summary of the company's earnings call · Paraphrased · Not investment advice
of shares held by institutions
222 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Pictet Asset Management Ltd | 1.09M | ▲ 269.59K |
| Parametric Portfolio Associates LLC | 43.88K | ▼ 53.89K |
| Indexiq Advisors LLC | 14.13K | ▲ 14.13K |
| Amalgamated Financial Corp. | 5.76K | ▲ 5.76K |
| Qs Investors, LLC | 3.30K | 0 |
| Burrage Capital Management LLC | 2.16K | ▼ 70.00K |
| First Mercantile Trust Co | 1.10K | ▼ 45 |
| Berman Capital Advisors, LLC | 12 | ▲ 12 |
Held by 1 ETFs
Biggest fund positions in TPTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 22 | Nicholson Garry A | sell | 23,400 |
| Aug 17, 22 | Nicholson Garry A | sell | 8,500 |
| Aug 17, 22 | Nicholson Garry A | sell | 8,500 |
| Aug 17, 22 | Machado Patrick | sell | 30,000 |
| Aug 17, 22 | George Simeon | sell | 8,500 |
| Aug 17, 22 | Gallagher Carol Giltner | sell | 8,500 |
| Aug 17, 22 | Gallagher Carol Giltner | sell | 30,000 |
| Aug 17, 22 | Gallagher Carol Giltner | sell | 8,500 |
| Aug 17, 22 | Gallagher Carol Giltner | sell | 8,500 |
| Aug 17, 22 | Bodem Barbara W. | sell | 14,995 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TPTX coverage
Recent articles, reports, and earnings notes.
No research on TPTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TPTX report →Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
businesswire.com · Aug 16
TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders
businesswire.com · Jul 5
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX
businesswire.com · Jul 5
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX
businesswire.com · Jul 5
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX
businesswire.com · Jun 5
Biotech ETFs Strengthen as Bristol Myers Squibb Buys Turning Point
etftrends.com · Jun 3
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Turning Point Therapeutics, Inc. Buyout
newsfilecorp.com · Jun 3
Turning Point Therapeutics' Shares Soar on Bristol-Myers Squibb Deal
gurufocus.com · Jun 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.